Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer

Inclusion Criteria: * Participants must have a biopsy confirmed diagnosis of squamous cell, adenocarcinoma, or adenosquamous carcinoma of the cervix. Histologic confirmation of the original primary tumor is required. * Participants with HRLACC. * Participants included those with stage IB2, IIA2, IIB with pelvic lymph node metastases; all FIGO Stage IIIA, IIIB, IVA or any FIGO Stage (except stage IVB) with para-aortic lymph node metastases as defined by the FIGO 2014 staging criteria for carcinoma of the cervix uteri. * Participants must have received definitive therapy with curative intent, which consist of at least 4 weeks of treatment with cisplatin and a minimum of 40Gy external beam radiation therapy (EBRT). * Have performance status of 0 or 1 on the gynaecologic Oncology Group (GOG) performance scale * Demonstrate adequate organ function Exclusion Criteria: * Has not achieved disease-free status after completion of CCRT administered with curative intent. * Has International Federation of Gynecology and Obstetrics (FIGO) Stage IVB * Has histologies other than squamous cell, adenocarcinoma, or adenosquamous carcinoma of the cervix. * Has implanted medical device(s) that pose a high risk for colonization and/or cannot be easily removed (e.g., prosthetic joints, artificial heart valves, pacemakers, orthopedic screw(s), metal plate(s), bone graft(s), or other exogenous implant(s)). * Has a contraindication (sensitivity or allergy) to trimethoprim/sulfamethoxazole and ampicillin. * Has undergone a previous hysterectomy defined as removal of the entire uterus or will have a hysterectomy as part of their initial cervical cancer therapy. NOTE: Women who have had a partial/subtotal hysterectomy are eligible to participate in the study